Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 9/20 | 1.00 |
| ▸ | DAO | P14920 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902532 | 1.00 | PDE3B (1.00) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL30154352 | 0.83 | PDE3B (0.71) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL3385284 | 0.83 | PDE3B (0.71) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL25903981 | 0.76 | PDE3B (0.61) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL7097549 | 0.75 | PDE3B (0.60) | PDE3BPDE3ADAOPARP1MAPT | |
| SCHEMBL35211851 | 0.74 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL1357945 | 0.74 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL7051447 | 0.73 | PDE3B (0.58) | PDE3BPDE3ADAOKDM5APARP1 | |
| SCHEMBL4287747 | 0.72 | PDE3B (0.57) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL4287824 | 0.71 | CYP11B2 (0.57) | PDE3BPDE3AF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| EP-0636027-A1 | ANGIOTENSIN II ANTAGONISTS AGAINST DISORDERS ASSOCIATED WITH IMPAIRED NEURONAL CONDUCTION VELOCITY, ESPECIALLY DIABETIC NEUROPATHY | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | claimed |
| WO-1994000450-A1 | CHROMANDERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | ZENECA LIMITED (GB) | 1994-01-06 | — | — | WO | claimed |
| WO-1993024501-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| WO-1993024487-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| WO-1993020816-A1 | ANGIOTENSIN II ANTAGONISTS AGAINST DISORDERS ASSOCIATED WITH IMPAIRED NEURONAL CONDUCTION VELOCITY, ESPECIALLY DIABETIC NEUROPATHY | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| EP-0234516-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINE CONTAINING THEM FOR THE TREATMENT OF VASCULAR DISEASES | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1992-04-29 | — | — | EP | claimed |
| EP-0173933-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-11-29 | — | — | EP | claimed |
| EP-0133530-B1 | 1,6-NAPHTHYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-03-15 | — | — | EP | claimed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | claimed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PDE3B 2661/4885PDE3A 3130/4885DAO 4594/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | PDE3B 2726/4885PDE3A 2033/4885DAO 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.